Maji Samir K, Schubert David, Rivier Catherine, Lee Soon, Rivier Jean E, Riek Roland
Structural Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, United States of America.
PLoS Biol. 2008 Feb;6(2):e17. doi: 10.1371/journal.pbio.0060017.
Amyloids are highly organized protein aggregates that are associated with both neurodegenerative diseases such as Alzheimer disease and benign functions like skin pigmentation. Amyloids self-polymerize in a nucleation-dependent manner by recruiting their soluble protein/peptide counterpart and are stable against harsh physical, chemical, and biochemical conditions. These extraordinary properties make amyloids attractive for applications in nanotechnology. Here, we suggest the use of amyloids in the formulation of long-acting drugs. It is our rationale that amyloids have the properties required of a long-acting drug because they are stable depots that guarantee a controlled release of the active peptide drug from the amyloid termini. This concept is tested with a family of short- and long-acting analogs of gonadotropin-releasing hormone (GnRH), and it is shown that amyloids thereof can act as a source for the sustained release of biologically active peptides.
淀粉样蛋白是高度有序的蛋白质聚集体,与神经退行性疾病如阿尔茨海默病以及皮肤色素沉着等良性功能相关。淀粉样蛋白通过募集其可溶性蛋白质/肽对应物以成核依赖的方式进行自我聚合,并且对恶劣的物理、化学和生物化学条件具有稳定性。这些非凡的特性使淀粉样蛋白在纳米技术应用中具有吸引力。在此,我们建议在长效药物制剂中使用淀粉样蛋白。我们的理论依据是,淀粉样蛋白具有长效药物所需的特性,因为它们是稳定的储存库,可确保活性肽药物从淀粉样蛋白末端可控释放。这一概念通过促性腺激素释放激素(GnRH)的一系列短效和长效类似物进行了测试,结果表明,其淀粉样蛋白可作为生物活性肽持续释放的来源。